Src mutation induces acquired lapatinib resistance in ERBB2-amplified human gastroesophageal adenocarcinoma models.
ERBB2-directed therapy is now a routine component of therapy for ERBB2-amplified metastatic gastroesophageal adenocarcinomas. However, there is little knowledge of the mechanisms by which these tumors develop acquired resistance to ERBB2 inhibition. To investigate this question we sought to characte...
Main Authors: | Yong Sang Hong, Jihun Kim, Eirini Pectasides, Cameron Fox, Seung-Woo Hong, Qiuping Ma, Gabrielle S Wong, Shouyong Peng, Matthew D Stachler, Aaron R Thorner, Paul Van Hummelen, Adam J Bass |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4211679?pdf=render |
Similar Items
-
Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.
by: Rama Krishna Kancha, et al.
Published: (2011-01-01) -
Dual HER2 blockade with lapatinib and trastuzumab in combination with chemotherapy in metastatic gastroesophageal adenocarcinoma
by: E. Von Cheong, et al.
Published: (2021-04-01) -
Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains
by: Timothy J. Stuhlmiller, et al.
Published: (2015-04-01) -
Lapatinib in combination with capecitabine in the management of ErbB2-positive (HER2-positive) advanced breast cancer
by: Bella Kaufman, et al.
Published: (2008-03-01) -
Anticancer Effect of Fucoidan in Combination with Tyrosine Kinase Inhibitor Lapatinib
by: Byeongsang Oh, et al.
Published: (2014-01-01)